Overview
NVS market data
Price History
NVS price chart
Valuation & Profitability
- P/E (TTM)
- 22.01 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $7.15 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.17 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 289.8% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $91.20 – $131.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $228.8K · P/B 5.55 · P/S 4.95.
Company news
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool · Jul 22, 2026, 11:00 AM
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035Globenewswire Inc · Jul 22, 2026, 11:00 AM
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in USBenzinga · Jul 22, 2026, 2:13 AM
Novartis Q2 2026 Earnings Call TranscriptBenzinga · Jul 21, 2026, 1:45 PM
Novartis Silences Generic Fears With Blowout Quarter, Packed PipelineBenzinga · Jul 21, 2026, 12:21 PM
Novartis shares are trading higher after the company reported better-than-expected Q2 financial resultsBenzinga · Jul 21, 2026, 11:43 AM
Earnings Scheduled For July 21, 2026Benzinga · Jul 21, 2026, 11:11 AM
Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2Benzinga · Jul 21, 2026, 5:10 AM
Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B EstimateBenzinga · Jul 21, 2026, 5:05 AM
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesGlobenewswire Inc · Jul 20, 2026, 4:15 PM